The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study
Open accessAbstract
Aims/hypothesis Recent European guidelines for non-alcoholic fatty liver disease (NAFLD) call for reference values for HOMA-IR. In this study, we aimed to determine: (1) the upper limit of normal HOMA-IR in two population-based cohorts; (2) the HOMA-IR corresponding to NAFLD; (3) the effect of sex and PNPLA3 genotype at rs738409 on HOMA-IR; and (4) inter-laboratory variations in HOMA-IR.Methods We identified healthy individuals in two population-based cohorts (FINRISK 2007 [n = 5024] and the Programme for Prevention of Type 2 Diabetes in Finland [FIN-D2D; n = 2849]) to define the upper 95th percentile of HOMA-IR. Non-obese individuals with normal fasting glucose levels, no excessive alcohol use, no known diseases and no use of any drugs were considered healthy. The optimal HOMA-IR cut-off for NAFLD (liver fat ≥5.56%, based on the Dallas Heart Study) was determined in 368 non-diabetic individuals (35% with NAFLD), whose liver fat was measured using proton magnetic resonance spectroscopy (1 H-MRS). Samples from ten individuals were simultaneously analysed for HOMA-IR in seven European laboratories.Results The upper 95th percentiles of HOMA-IR were 1.9 and 2.0 in healthy individuals in the FINRISK (n = 1167) and FIN-D2D (n = 459) cohorts. Sex or PNPLA3 genotype did not influence these values. The optimal HOMA-IR cut-off for NAFLD was 1.9 (sensitivity 87%, specificity 79%). A HOMA-IR of 2.0 corresponded to normal liver fat (<5.56% on 1 H-MRS) in linear regression analysis. The 2.0 HOMA-IR measured in Helsinki corresponded to 1.3, 1.6, 1.8, 1.8, 2.0 and 2.1 in six other laboratories. The inter-laboratory CV% of HOMA-IR was 25% due to inter-assay variation in insulin (25%) rather than glucose (5%) measurements.Conclusions/interpretation The upper limit of HOMA-IR in population-based cohorts closely corresponds to that of normal liver fat. Standardisation of insulin assays would be the first step towards definition of normal values for HOMA-IR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“insulin resistance can also be measured clinically with the HOMA-IR index from fasting insulin or C-peptide and fasting glucose concentrations, including in people with T2D (unless on insulin treatment). 219 -221”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [220]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Kumar, M. V. J., & Chippada, A. R. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–120 of 120
Nonalcoholic fatty liver disease
van Son, K. C., Holleboom, A. G., & Tushuizen, M. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00024-9
Chávez-Pagola, J. T., Hernández‐Zavala, A., Valenzuela-Limon, O., Sánchez‐Gutiérrez, M., & Vega, J. A. I. (2022) · International Journal of Medicine · doi:10.14419/ijm.v10i1.32185
Evaluation of Insulin Resistance of Individuals with MAFLD
Koç, Z., Aladağ, N., ÇAKIR, H., & Akın, S. (2023) · Hippocrates Medical Journal · doi:10.58961/hmj.1190766
Ku, G. D. L. C., Zevallos, A., Rázuri-Bustamante, C. R., Kalipatnapu, S., Príncipe-Meneses, F. S., Dongo, P., Chambergo‐Michilot, D., Salinas-Sedo, G., & Valcarcel-Valdivia, B. (2023) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2022.0043
Lee, H., & Lee, J. (2023) · Korean Journal of Family Practice · doi:10.21215/kjfp.2023.13.4.233
Song, L., Gao, Y., Tian, J., Liu, N., Nasier, H., Wang, C., Zhen, H., Guan, L., Niu, Z., Shi, D., et al. (2024) · Environmental Science and Pollution Research · doi:10.1007/s11356-024-32255-8
Волкова, Н. И., Davidenko, I. Y., Sorokina, Y. A., Degtyareva, Y. S., Vlasova, N. D., & Baeva, D. O. (2024) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2024-13-1-27-34
Davidenko, I. Y., Sorokina, Y. A., Волкова, Н. И., & Degtyareva, Y. S. (2024) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2024-15-2-61-68
Simon, L., Lin, H., Poret, J. M., Stouwe, C. V., Ferguson, T. F., Welsh, D. A., & Molina, P. E. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15464
Tang, X., Wang, F., Gao, Y., Liu, Y., Zhao, S.-L., Lu, J. L., Qin, J., & Zhang, B. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5061164
Abdul-Wahab, S., & Saeed, G. T. (2025) · Obat · doi:10.61132/obat.v3i1.969
Nádasdi, Á., & Firneisz, G. (2025) · Orvosi Hetilap · doi:10.1556/650.2025.33421
Colantoni, A., Bucci, T., Cocomello, N., Angelico, F., Ettorre, E., Pastori, D., Lip, G. Y. H., Ben, M. D., & Baratta, F. (2024) · Figshare · doi:10.6084/m9.figshare.25865096
Fatty pancreas and its relation to insulin resistance and adiponectin level in non-diabetic patients
Abdelfatah, Y., Hashim, A. M., Shaker, O. G., Mostafa, A. M., & Hassan, M. B. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00594-2
Yu, Q., Lin, Y.-Y., Gui, Z.-H., Duan, H.-L., Yang, J.-J., Meng, Y., Peng, X.-T., Lan, L., Wan, H., & Shen, J. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i21.118057
Toghan, R., Salem, T. A., Dongol, E. M., Hamdan, F. R. A., Ahmed, O., Ali, A. M. S., Hassan, M. H., Abdelhady, M., & Abdel-Aziz, R. H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15134861
Joint association of body roundness index and HOMA-IR with risk of MASLD in Korean populations
Lee, K.-S., Ahn, S.-H., Son, D., & Lee, Y. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02361-4
Driuchina, A., Hekkala, J., Hintikka, J. E., Permi, P., Hellsten, E., Lensu, S., Bielik, V., Laukkanen, J. A., & Pekkala, S. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01168-3
CUERVO-PARDO, N., Kalavalapalli, S., Leiva, E. G., Rocha, A. O., Barb, D., Sharma, A., Jens, R., Bril, F., Connelly, M. A., Grajo, J. R., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.031
Chen, Y., Li, Y., Li, X., Xu, X., & Chen, S. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1962509
Metadata
- Authors
- Isokuortti, E., Zhou, Y., Peltonen, M., Bugianesi, E., Clement, K., Bonnefont-Rousselot, D., Lacorte, J.-M., Gastaldelli, A., Schuppan, D., Schattenberg, J. M., Hakkarainen, A., Lundbom, N., Jousilahti, P., Männistö, S., Keinänen-Kiukaanniemi, S., Saltevo, J., Anstee, Q. M., & Yki-Järvinen, H.
- Affiliations
- University of Helsinki (FI)
- Cardiff University (GB)
- Finnish Institute for Health and Welfare (FI)
- University of Turin (IT)
- Inserm (FR)
- Istituto di Fisiologia Clinica (IT)
- Johannes Gutenberg University Mainz (DE)
- Central Finland Health Care District (FI)
- Freeman Hospital (GB)
- Corresponding author
- Isokuortti, Elina
- ORCID
- Venue
- Diabetologia
- Published
- 2017-06-29
- Volume
- 60
- Issue
- 10
- Pages
- 1873-1882
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2728177312
- Cited by
- 120
- References
- 49
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 20 · 2023: 9 · 2022: 18 · 2021: 12 · 2020: 20 · 2019: 14 · 2018: 6 · 2017: 3
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- HAL (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- The Novo Nordisk Foundation
- Suomen Akatemia
- Paulon Säätiö
- Horizon 2020 Framework Programme (Grant Agreement 634413)
- The Sigrid Juselius Foundation
- Suomen Lääketieteen Säätiö
- EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant no. 115372)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, HOMA-IR, insulin resistance, reference values, upper limit of normal, diagnostic thresholds, PNPLA3 rs738409, sex differences, inter-laboratory variability, liver fat, 1H NMR, type 2 diabetes prevention
- MeSH terms
- Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Middle Aged, Reference Values, Adiposity, Young Adult, Antibodies, Monoclonal, Humanized, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
